Abstract: The present invention provides sustained-release oral pharmaceutical compositions and methods of use. The sustained-release oral pharmaceutical compositions include an opioid (including salts thereof) and a salt of a non-steroidal anti-inflammatory drug (NSAID).

Abstract: Sustained-release oral pharmaceutical compositions and methods of use, wherein the compositions are in a single dosage form and include an amine-containing compound (including salts thereof), a salt of a non-steroidal anti-inflammatory drug (NSAID), and a hydrophilic matrix.

Abstract: Dermatological compositions (methods of making and using) that include one or more anesthetic agents and/or one or more anti-inflammatory agents and/or a combination of ammonium, sodium, and potassium salts, preferably of an alpha-hydroxy acid.

Abstract: The present invention provides sustained-release oral pharmaceutical compositions and methods of use. The sustained-release oral pharmaceutical compositions include an opioid (including salts thereof) and a salt of a non-steroidal anti-inflammatory drug (NSAID).

Abstract: Dermatological compositions (methods of making and using) that include one or more anesthetic agents and/or one or more anti-inflammatory agents and/or a combination of ammonium, sodium, and potassium salts, preferably of an alpha-hydroxy acid.

Abstract: Dermatological compositions (methods of making and using) that include one or more anesthetic agents and/or one or more anti-inflammatory agents and/or a combination of ammonium, sodium, and potassium salts, preferably of an alpha-hydroxy acid.

Abstract: This invention provides extended release potassium chloride granules consisting essentially of potassium chloride crystals having a mesh size of about 20–60 mesh that are coated only with ethylcellulose. The granules may be compressed into tablets that disintegrate rapidly in an aqueous environment to provide uniform dissolution of the potassium chloride. Tablets containing about 10 to about 20 milliequivalents potassium may be formulated in accordance with the invention. Processes to produce extended release granules without using surfactants, processing aids or other coating aids are also provided by this invention. A method is further provided whereby a patient's supplemental potassium requirements are met by administering an appropriate combination of dosage units chosen from available dosage units containing different quantities of potassium.

Abstract: The present invention provides emollient creams composed of sulfur, sodium sulfacetamide and a botanically-derived anti-inflammatory ingredient. The creams are alcohol-free and have a pH at or above 7.0.

Abstract: This invention provides extended release potassium chloride granules consisting essentially of potassium chloride crystals having a mesh size of about 20-60 mesh that are coated only with ethylcellulose. The granules may be compressed into tablets that disintegrate rapidly in an aqueous environment to provide uniform dissolution of the potassium chloride. Tablets containing about 10 to about 20 milliequivalents potassium may be formulated in accordance with the invention. Processes to produce extended release granules without using surfactants, processing aids or other coating aids are also provided by this invention. A method is further provided whereby a patient's supplemental potassium requirements are met by administering an appropriate combination of dosage units chosen from available dosage units containing different quantities of potassium.

Abstract: Dermatological compositions (methods of making and using) that include one or more anesthetic agents and/or one or more anti-inflammatory agents and/or a combination of ammonium, sodium, and potassium salts, preferably of an alpha-hydroxy acid.

Abstract: This invention provides extended release potassium chloride granules consisting essentially of potassium chloride crystals having a mesh size of about 20-60 mesh that are coated only with ethylcellulose. The granules may be compressed into tablets that disintegrate rapidly in an aqueous environment to provide uniform dissolution of the potassium chloride. Tablets containing about 10 to about 20 milliequivalents potassium may be formulated in accordance with the invention. Processes to produce extended release granules without using surfactants, processing aids or other coating aids are also provided by this invention. A method is further provided whereby a patient's supplemental potassium requirements are met by administering an appropriate combination of dosage units chosen from available dosage units containing different quantities of potassium.

Abstract: Apparatus and method for retaining cotton in a bottle using a cottoner machine which inserts cotton via a pair of rotatable cylinders alignable with a mouth of the bottle, the apparatus including a disk secured to the cylinders via a pair of collars and having a pair of apertures aligned with the cylinders, and the method including a process of positioning a planar surface of the disk closely superjacent the mouth of the bottle after insertion of the cotton.

Abstract: Apparatus and method for retaining cotton in a bottle using a cottoner machine which inserts cotton via a pair of rotatable cylinders alignable with a mouth of the bottle, the apparatus including a disk secured to the cylinders via a pair of collars and having a pair of apertures aligned with the cylinders, and the method including a process of positioning a planar surface of the disk closely superjacent the mouth of the bottle after insertion of the cotton.

Abstract: The invention provides a pharmaceutical composition which is a combination of an insulin-secretion stimulant and a HMG-CoA reductase inhibitor. Suitable insulin-secretion stimulants include the sulfonylurea drugs, and suitable HMG-CoA reductase inhibitors include the statin drugs. The composition may be formulated to provide extended-release characteristics of one or both of the active components. Also provided are methods for treating a diabetic patient using a combination of an insulin-secretion stimulant and a HMG-CoA reductase inhibitor. Practice of the methods of the invention may result in the administration of fewer dosages to the patient. The invention also provides a pharmaceutical composition which is a combination of an antihyperglycemic drug, particularly a biguanide compound, in combination with a HMG-CoA reductase inhibitor. Also provided are methods for treating a diabetic patient using a combination of an antihyperglycemic biguanide compound and a HMG-CoA reductase inhibitor.

Abstract: St. John's Wort has been indicated as a beneficial supplement to human diet. It has been traditionally provided as an extract, tincture, tea or capsule form, usually administered in amounts taken three times/day. It has been found that the manufacture of a tablet of this supplement material is a complex process, and that St. John's Wort extract is not amenable to wet tableting. A tablet which can be taken twice a day to provide a recommended supplemental level of St. John's Wort is described as comprising by weight of the tablet: 400 to 500 mg St. John's Wort extract as 57 to 75% by weight of the tablet, 1.0-5.0% by weight binder, 8-18% by weight dissolution regulator, up to 30% by weight filler, 0.2 to 5.0% by weight glidant, and 0.5 to 2.5% by weight lubricant/glidant. A process for manufacturing the tablet comprises the steps of a) mixing components comprising: 400 to 500 mg St. John's Wort extract as 57 to 75% by weight of the tablet, 1.0-5.

Abstract: A vitamin B12 supplement composition comprising vitamin B12 with and/or without added folic acid that is essentially free of antioxidants, such as vitamin C, as well as iron is disclosed. Also disclosed are methods of using this vitamin composition to prevent brain and nervous system damage, such as peripheral nerve damage, as well as pernicious anemia, such as where such anemia is caused by a deficiency of vitamin B12 deficiency.

Abstract: Apparatus and method for retaining cotton in a bottle using a cottoner machine which inserts cotton via a pair of rotatable cylinders alignable with a mouth of the bottle, the apparatus including a disk secured to the cylinders via a pair of collars and having a pair of apertures aligned with the cylinders, and the method including a process of positioning a planar surface of the disk closely superjacent the mouth of the bottle after insertion of the cotton.

Abstract: A method of treating and/or preventing renal dysfunction in a patient, such as renal colic or contrast nephropathy by administering to a patient, a compound of the formula: is described herein. Administration of dyphylline in a sustained release oral dosage form is preferred.

Abstract: A method of treating and/or preventing renal dysfunction in a patient, such as renal colic or contrast nephropathy by administering to a patient, a compound of the formula: is described herein. Administration of dyphylline in a sustained release oral dosage form is preferred.

Abstract: A vitamin B12 supplement composition comprising vitamin B12 with and/or without added folic acid that is essentially free of antioxidants, such as vitamin C, as well as iron is disclosed. Also disclosed are methods of using this vitamin composition to prevent brain and nervous system damage, such as peripheral nerve damage, as well as pernicious anemia, such as where such anemia is caused by a deficiency of vitamin B12 deficiency.